This Cancer Drug Comparable Report outlines the approximate costs associated with taking one of our Cancer Drugs through the FDA Clinical trials for...This Cancer Drug Comparable Report outlines the approximate costs associated with taking one of our Cancer Drugs through the FDA Clinical trials for commercialization. It also outlines the current Comparable Drug Values on the market today.
Once our Cancer Killing Drugs are approved through the FDA process, Doctors Nationwide (Right across the country, in every State) can write a prescription for our low-cost Cancer Killing Drugs.
*** Please click the Image on the left to review the full Report.
The FDA IND# Application is our next step. We are ready to start the “Pharmacokinetics Translation” (approx. 3-6 months with funding in place) this is the translation report comprised from all of the successful extensive preclinical work we did as per the (2) Frontiers Reports, demonstrating efficacy and safety profiles, de-risked in the mice studies, and “Ready for Human Clinical Trials”.
The Pharmacokinetics Translation report is part of the FDA Investigational New Drug (IND) Application to begin Phase 1 Clinical Trials.
This is the MAIN reason we are doing the 1-Million Strong Killing Cancers VIP Fundraiser Events. We plan to raise the money through the markets and through the 1-Million Strong Fundraiser Events until we are ready to begin.
Having "EBYH" as one of the funding Partners and "Presenters" with Cannabis Science at the Inaugural Fundraiser is key. It will certainly raise the Status and Value of both "EBYH" and Cannabis Science with a Successful Cancer Drug commercialization under its belt.
Cheers Guys!
"We are certainly on our way to the FDA"
Hopefully we'll see you at the Event.
All the Best
Raymond - IGWT
Show more
Click the above Image to Review our Cancer Drug Comparables
*** Warning this document contains graphic images.
Click Logo for Current News Release
The CSi-VIP & CSi-VIP Legacy Drug Ownership Programs are closing. Please Click the above Calendar Link to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
This Cancer Drug Comparable Report outlines the approximate costs associated with taking one of our Cancer Drugs through the FDA Clinical trials for...This Cancer Drug Comparable Report outlines the approximate costs associated with taking one of our Cancer Drugs through the FDA Clinical trials for commercialization. It also outlines the current Comparable Drug Values on the market today.
Once our Cancer Killing Drugs are approved through the FDA process, Doctors Nationwide (Right across the country, in every State) can write a prescription for our low-cost Cancer Killing Drugs.
*** Please click the Image on the left to review the full Report.
The FDA IND# Application is our next step. We are ready to start the “Pharmacokinetics Translation” (approx. 3-6 months with funding in place) this is the translation report comprised from all of the successful extensive preclinical work we did as per the (2) Frontiers Reports, demonstrating efficacy and safety profiles, de-risked in the mice studies, and “Ready for Human Clinical Trials”.
The Pharmacokinetics Translation report is part of the FDA Investigational New Drug (IND) Application to begin Phase 1 Clinical Trials.
This is the MAIN reason we are doing the 1-Million Strong Killing Cancers VIP Fundraiser Events. We plan to raise the money through the markets and through the 1-Million Strong Fundraiser Events until we are ready to begin.
Having "EBYH" as one of the funding Partners and "Presenters" with Cannabis Science at the Inaugural Fundraiser is key. It will certainly raise the Status and Value of both "EBYH" and Cannabis Science with a Successful Cancer Drug commercialization under its belt.
Cheers Guys!
"We are certainly on our way to the FDA"
Hopefully we'll see you at the Event.
All the Best
Raymond - IGWT
Show more
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
We have a few good conference calls setup to progress our 1-Million Strong Killing Cancers VIP... Show more 1 month ago
The Dow is poised to build on record as stocks rise ahead of... Show more 4 weeks ago
Our newest ASU/CSi-EDP Partner "EBYH" is getting ready for the Brand New 1-Million Strong VIP... Show more 4 weeks ago